Loading clinical trials...

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NCT04913337•NGM Biopharmaceuticals, Inc

View on ClinicalTrials.gov

Summary

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
•Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type, and for which the patient was eligible and willing to receive, or refused SOC treatments that are perceived to have marginal clinical benefit.
•Adequate bone marrow, kidney and liver function.
•Performance status of 0 or 1.
•Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.

Exclusion Criteria

•Prior treatment targeting ILT2 and/or ILT4 or targeting HLA-G.

Locations (27)

NGM Clinical Study Site

Los Angeles, California, United States

NGM Clinical Study Site

Newport Beach, California, United States

NGM Clinical Study Site

Santa Monica, California, United States

NGM Clinical Study Site

Santa Rosa, California, United States

NGM Clinical Study Site

Lone Tree, Colorado, United States

NGM Clinical Study Site

Washington D.C., District of Columbia, United States

NGM Clinical Study Site

Sarasota, Florida, United States

NGM Clinical Study Site

Baltimore, Maryland, United States

NGM Clinical Study Site

Boston, Massachusetts, United States

NGM Clinical Study Site

Grand Rapids, Michigan, United States

Key Dates

Start Date

June 9, 2021

Primary Completion Date

February 1, 2025

Completion Date

July 1, 2025

Last Updated

October 2, 2024

Enrollment

179

ESTIMATED participants

Conditions

MesotheliomaGlioblastomaRenal Cell CarcinomaNon Small Cell Lung CancerMelanomaPancreatic Ductal AdenocarcinomaGastric CancerSquamous Cell Carcinoma of Head and NeckCholangiocarcinomaBreast CancerOvarian CancerCervical CancerEndocervical CancerColorectal CancerEsophageal Cancer

Interventions

NGM707

DRUG

NGM707 plus pembrolizumab (KEYTRUDA®)

DRUG

NGM707 plus pembrolizumab (KEYTRUDA®)

DRUG

NGM707 plus pembrolizumab (KEYTRUDA®)

DRUG

NGM707 plus pembrolizumab (KEYTRUDA®)

DRUG

NGM707

DRUG

NGM707

DRUG

NGM707

DRUG

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

View study

RECRUITING

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

NCT00083512

Glioblastoma Multiforme

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 2, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Inclusion Criteria

Exclusion Criteria

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Targeted Pediatric High-Grade Glioma Therapy

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma